Sotera Health (NASDAQ:SHC) Updates FY 2026 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.930-1.01 for the period, compared to the consensus EPS estimate of 0.910. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Ratings Changes

Several research analysts have weighed in on the company. BMO Capital Markets assumed coverage on Sotera Health in a research report on Thursday, November 13th. They set an “outperform” rating and a $19.00 price target on the stock. Royal Bank Of Canada began coverage on Sotera Health in a report on Thursday, January 8th. They issued an “outperform” rating and a $24.00 price objective for the company. Zacks Research downgraded shares of Sotera Health from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Barclays upped their price target on shares of Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Sotera Health in a research note on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Sotera Health Price Performance

SHC opened at $17.49 on Tuesday. Sotera Health has a 1-year low of $9.53 and a 1-year high of $19.85. The stock’s fifty day simple moving average is $17.99 and its 200 day simple moving average is $16.81. The company has a current ratio of 2.38, a quick ratio of 2.18 and a debt-to-equity ratio of 4.04. The stock has a market cap of $4.97 billion, a PE ratio of 92.06 and a beta of 1.82.

Insider Activity

In other news, CEO Michael B. Jr. Petras sold 434,104 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $16.45, for a total value of $7,141,010.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pincus & Co. Warburg sold 9,720,000 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total transaction of $158,727,600.00. Following the sale, the director owned 34,102,952 shares of the company’s stock, valued at approximately $556,901,206.16. This represents a 22.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 17,384,104 shares of company stock valued at $284,024,511 over the last ninety days. 55.12% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sotera Health

A number of institutional investors have recently made changes to their positions in SHC. Empowered Funds LLC increased its stake in shares of Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock worth $332,000 after purchasing an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Sotera Health by 14.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after buying an additional 43,471 shares in the last quarter. Acadian Asset Management LLC increased its position in Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after buying an additional 14,018 shares during the period. Creative Planning increased its position in Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock worth $224,000 after buying an additional 2,673 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Sotera Health by 4.2% during the second quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock worth $3,549,000 after buying an additional 12,758 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.